| Followers | 239 |
| Posts | 15508 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Tuesday, October 17, 2017 6:30:11 PM
I believe Avii wants to locate it (the Act IV Rindo protocol that is supposed to be attached to the Lancet Journal article and is not) so he can further compare that trial's selection criteria to DCVax-L's. Primarily, he wants to see how the MRI's were used in that prior to actually enrolling patients in the Rindo trial. He knows how they were used for the DCVax-L trial - to prevent rapid and chemo/rad pseudo-progressors from entering the main arm of this trial.
But he wants the criteria for how they were used to for the Rindo trial. Did they exclude rapid progressors or allow them in? If they excluded them, and included psPD patients, than that would mean they removed those likely to die first and kept those likely to die last (apologies for putting that so crudely). If this were the case, and DCVax-L still had a better comparison, that would be more remarkable.
However, if they removed both rapid and psPD, than the comparison of patients as they began the trial would be more equal. I hope this makes sense. I believe that's what and why Avii wants the protocol.
https://www.investorvillage.com/smbd.asp?mb=6543&mn=10361&pt=msg&mid=17615979
But he wants the criteria for how they were used to for the Rindo trial. Did they exclude rapid progressors or allow them in? If they excluded them, and included psPD patients, than that would mean they removed those likely to die first and kept those likely to die last (apologies for putting that so crudely). If this were the case, and DCVax-L still had a better comparison, that would be more remarkable.
However, if they removed both rapid and psPD, than the comparison of patients as they began the trial would be more equal. I hope this makes sense. I believe that's what and why Avii wants the protocol.
https://www.investorvillage.com/smbd.asp?mb=6543&mn=10361&pt=msg&mid=17615979
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
